Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1968 2
1969 7
1970 4
1971 4
1972 2
1973 2
1974 2
1975 2
1976 12
1977 2
1978 6
1979 1
1980 7
1981 8
1982 11
1983 15
1984 6
1985 12
1986 7
1987 3
1988 5
1989 11
1990 5
1991 4
1992 14
1993 4
1994 7
1995 8
1996 7
1997 13
1998 13
1999 11
2000 5
2001 8
2002 15
2003 13
2004 33
2005 22
2006 32
2007 23
2008 26
2009 27
2010 32
2011 41
2012 49
2013 50
2014 44
2015 43
2016 46
2017 39
2018 39
2019 39
2020 73
2021 73
2022 81
2023 76
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,045 results

Results by year

Filters applied: . Clear all
Page 1
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Among authors: nishiyama h. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: nishiyama h. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Bellmunt J, et al. Among authors: nishiyama h. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D'Alessio D; SURPASS-CVOT investigators. Nicholls SJ, et al. Among authors: nishiyama h. Am Heart J. 2024 Jan;267:1-11. doi: 10.1016/j.ahj.2023.09.007. Epub 2023 Sep 25. Am Heart J. 2024. PMID: 37758044 Free article. Clinical Trial.
This issue 31-2.
Nishiyama H. Nishiyama H. Int J Urol. 2024 Feb;31(2):97. doi: 10.1111/iju.15400. Int J Urol. 2024. PMID: 38308851 No abstract available.
Perioperative therapies for urological cancers.
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y. Inokuchi J, et al. Among authors: nishiyama h. Jpn J Clin Oncol. 2020 Apr 7;50(4):357-367. doi: 10.1093/jjco/hyaa013. Jpn J Clin Oncol. 2020. PMID: 32115649 Review.
Epidemiology of urothelial carcinoma.
Miyazaki J, Nishiyama H. Miyazaki J, et al. Among authors: nishiyama h. Int J Urol. 2017 Oct;24(10):730-734. doi: 10.1111/iju.13376. Epub 2017 May 21. Int J Urol. 2017. PMID: 28543959 Review.
1,045 results